Turnstone Biologics Corporation (TSBX) Actualités

Form 4 - Statement of changes in beneficial ownership of securities

Form 4 - Statement of changes in beneficial ownership of securities

Form 4 - Statement of changes in beneficial ownership of securities

Form 4 - Statement of changes in beneficial ownership of securities

Form 4 - Statement of changes in beneficial ownership of securities

Turnstone Biologics to Present Preclinical Data for Selected Tumor-Infiltrating Lymphocyte (TIL) Therapy at Society for Immunotherapy of Cancer’s (SITC) 38th Annual Meeting

SAN DIEGO, Sept. 28, 2023 (GLOBE NEWSWIRE) -- Turnstone Biologics Corp. (“Turnstone” or the “Company”...

Turnstone Biologics Corp. Reports Second Quarter 2023 Financial Results and Provides Business Update

Successfully closed upsized IPO, raising $88 million in gross proceeds to continue advancing pipeline of...

Form 10-Q - Quarterly report [Sections 13 or 15(d)]

Turnstone Biologics Corp. Announces Pricing of Upsized Initial Public Offering

SAN DIEGO, July 20, 2023 (GLOBE NEWSWIRE) -- Turnstone Biologics Corp. (“Turnstone” or the “Company”...